KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Current Deferred Revenue (2019 - 2021)

Historic Current Deferred Revenue for Xenon Pharmaceuticals (XENE) over the last 6 years, with Q3 2021 value amounting to $2.2 million.

  • Xenon Pharmaceuticals' Current Deferred Revenue fell 7042.71% to $2.2 million in Q3 2021 from the same period last year, while for Sep 2021 it was $2.2 million, marking a year-over-year decrease of 7042.71%. This contributed to the annual value of $3.6 million for FY2020, which is 8775.51% down from last year.
  • Xenon Pharmaceuticals' Current Deferred Revenue amounted to $2.2 million in Q3 2021, which was down 7042.71% from $3.0 million recorded in Q2 2021.
  • Xenon Pharmaceuticals' Current Deferred Revenue's 5-year high stood at $29.7 million during Q4 2019, with a 5-year trough of $2.2 million in Q3 2021.
  • Moreover, its 3-year median value for Current Deferred Revenue was $5.5 million (2020), whereas its average is $10.9 million.
  • Per our database at Business Quant, Xenon Pharmaceuticals' Current Deferred Revenue plummeted by 8775.51% in 2020 and then tumbled by 7042.71% in 2021.
  • Quarter analysis of 3 years shows Xenon Pharmaceuticals' Current Deferred Revenue stood at $29.7 million in 2019, then plummeted by 87.76% to $3.6 million in 2020, then crashed by 39.54% to $2.2 million in 2021.
  • Its Current Deferred Revenue was $2.2 million in Q3 2021, compared to $3.0 million in Q2 2021 and $3.6 million in Q1 2021.